Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

Contributed by: PR Newswire

Tags

Celosia-Therapeutics

More Like This

PR Newswire associated0

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens

PR Newswire associated0

Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent